.Pharmacolibrary.Drugs.ATC.R.R03CC15

Information

Formoterol is a long-acting β2-adrenergic agonist (LABA) used as a bronchodilator for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is usually administered by inhalation and is approved and widely used today in combination with inhaled corticosteroids or alone.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after inhaled administration.

References

1. Kuna, P, et al., & Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. Pharmacology research & perspectives 10(4) e980–None. DOI:10.1002/prp2.980 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35733414

2. Chen, Q, et al., & Dorinsky, P (2019). Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. Clinical therapeutics 41(5) 897–909.e1. DOI:10.1016/j.clinthera.2019.03.007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30982547

3. Soulele, K, et al., & Karalis, V (2018). On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches. Pulmonary pharmacology & therapeutics 48 168–178. DOI:10.1016/j.pupt.2017.12.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29223508

Revisions

• 06/2025 initial generated model